Skip to main content

First Light Diagnostics Receives Additional $4.3M in BARDA Funding

NEW YORK — First Light Diagnostics said on Wednesday that it has received an additional $4.3 million in new funding under a technology development contract with the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). 

Under the contract, First Light is developing its MultiPath diagnostic platform, which uses digital imaging to count labeled bacterial cells or single molecules tagged with antibody-coated fluorescent nanoparticles, as well as assays for anthrax and urinary tract infection pathogen identification and culture-free antimicrobial susceptibility testing.

With the latest funding, First Light has received a total of $27.1 million from BARDA. 

In June, First Light secured $4.5 million in debt financing. A few months later, the Chelmsford, Massachusetts-based company closed an $8.3 million oversubscribed Series A-2 financing round.